|
|
| (10 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| | |
| | |
| | |
|
| |
|
| __NOTOC__ | | __NOTOC__ |
| {{CMG}}; {{AE}} {{NN}}<br> | | {{CMG}}; {{AE}} {{NN}}<br> |
| ---- | | ---- |
|
| |
| '''Acute Kidney Injury in COVID-19'''<br><br>
| |
| '''For patient information, click [[Xyz (patient information)|here]]'''
| |
|
| |
|
| |
|
| |
| {{SK}} [[Acute Kidney Injury]], [[Acute Renal Failure]], [[AKI]], [[ARF]]
| |
|
| |
| ==[[Xyz overview|Overview]]==
| |
|
| |
| =[[Xyz historical perspective|Historical Perspective]]=
| |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
| =[[Xyz classification|Classification]]= | | {{familytree/start}}{{familytree | | | | | | | | | A01 | | | | | |A01= [[COVID-19]] }} |
| | {{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }} |
| | {{familytree | | C01 | | | | | | | | | | | | C02 |C01= '''30-40%''' <br> [[Asymptomatic]]|C02= '''60-70%''' <br> [[Symptomatic]]}} |
| | {{familytree | | |!| | | | | | | | | |,|-|-|-|+|-|-|-|-|.|}} |
| | {{familytree | | E01 | | | | | | | | E02 | | E03 | | | E04 |E01=[[Asymptomatic carrier]]|E02='''80%''' <br> Mild symtoms|E03='''14%''' <br> Severe symptoms|E04='''6%''' <br> Critically ill}} |
| | {{familytree | | | | | | | | | | | | |!| | | |!| | | | |!| | }} |
| | {{familytree | | | | | | | | | | | | F01 | | F02 | | | F03 |F01=[[Fever]]<br> [[Chills]]<br> [[Cough]]<br> [[Headache]]<br> [[Sore throat]]<br> [[Nasal congestion]] or secretion <br> [[Fatigue]]<br> [[Body aches]]<br> [[loss of taste]] or [[smell]] |
| | <br> [[Nausea]] or [[vomiting]] <br> [[Diarrhea]]<br> |F02=Severe [[Dyspnea]]<br> [[Chest pain]]<br> Severe [[weakness]] <br> new [[Confusion]]<br> Central [[Cyanosis]] |
| | |F03=Death}} |
| | {{familytree/end}} |
|
| |
|
| =[[Xyz pathophysiology|Pathophysiology]]=
| |
|
| |
|
| *Angiotensin-converting enzyme 2 ([[ACE2]]), which is a primary receptor for [[SARS-CoV-2]] entry into cells, mostly presents in kidneys as well as lungs and heart.
| |
| *Despite kidney injury following [[COVID-19]] infection is less frequent than severe lung injury, [[ACE2]]: [[ACE]] ratio is higher in the kidneys compared to the respiratory system. (1:1 in the kidneys VS 1:20 in the respiratory system)
| |
|
| |
|
| | {| class="wikitable" |
| | ! colspan=4 style="background: #4479BA; color: #FFFFFF; " align="center"|CT manifestations of COVID-19 |
| | |- |
| | !style="background: #4479BA; color: #FFFFFF; " align="center" |CT findings |
| | !style="background: #4479BA; color: #FFFFFF; " align="center" |Definition |
| | !style="background: #4479BA; color: #FFFFFF; " align="center" |CT picture |
| | |- |
| | |style="background: #DCDCDC; |'''[[Ground glass opacity]]''' |
| | | |
| | *Hazy opacity in the lungs with well defined bronchial and vascular margins |
| | *the most common imaging finding |
| | *due to infection, chronic interstitial lung disease, and acute lung injury |
|
| |
|
| =[[Xyz causes|Causes]]=
| | |[[File:Covid-19-pneumonia-26.jpg|200px|thumb|center]] |
| *It is thought that [[AKI]] following COVID-19 is the result of<ref name="MalhaMueller2020">{{cite journal|last1=Malha|first1=Line|last2=Mueller|first2=Franco B.|last3=Pecker|first3=Mark S.|last4=Mann|first4=Samuel J.|last5=August|first5=Phyllis|last6=Feig|first6=Peter U.|title=COVID-19 and the Renin-Angiotensin System|journal=Kidney International Reports|volume=5|issue=5|year=2020|pages=563–565|issn=24680249|doi=10.1016/j.ekir.2020.03.024}}</ref>
| | |- |
| **[[Sepsis]] | | |style="background: #DCDCDC; |'''[[Consolidation]]''' |
| **Hypotension | | | |
| =[[Xyz differential diagnosis|Differentiating Xyz from other Diseases]]=
| | *a parenchymal density with ill-defined bronchial and vascular margins |
| | *filling with infectious material [fluid, cells, tissue] |
| | * due to cellular exudates in alveoli |
| | |[[file |
| | |- |
| | |style="background: #DCDCDC; |''' [[Crazy paving pattern]] ''' |
| | | |
| | * Septal thickening of inter and intra-lobar regions |
| | * with the background of the Ground glass opacity |
| | * Similar to paving stones |
| | * Due to alveolar edema and acute inflammation of the lung |
| | * Sign of progression |
| | |[[File:Covid-19-pneumonia-122.jpg|200px|thumb|center]] |
|
| |
|
| =[[Xyz epidemiology and demographics|Epidemiology and Demographics]]=
| |
| *Early reports from china revealed that COVID-19 rarely involves the kidneys, as [[Acute Renal Failure]] was not seen among COVID-19 hospitalized patients and just mild [[BUN]] or creatinine rise occurred. <ref name="WangLi2020">{{cite journal|last1=Wang|first1=Luwen|last2=Li|first2=Xun|last3=Chen|first3=Hui|last4=Yan|first4=Shaonan|last5=Li|first5=Dong|last6=Li|first6=Yan|last7=Gong|first7=Zuojiong|title=Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China|journal=American Journal of Nephrology|volume=51|issue=5|year=2020|pages=343–348|issn=0250-8095|doi=10.1159/000507471}}</ref>
| |
| *However, recent study found 75.4% of hospitalized patients with COVID-19 pneumonia developed [[hematuria]], [[proteinuria]], and [[AKI]]. <ref name="PeiZhang2020">{{cite journal|last1=Pei|first1=Guangchang|last2=Zhang|first2=Zhiguo|last3=Peng|first3=Jing|last4=Liu|first4=Liu|last5=Zhang|first5=Chunxiu|last6=Yu|first6=Chong|last7=Ma|first7=Zufu|last8=Huang|first8=Yi|last9=Liu|first9=Wei|last10=Yao|first10=Ying|last11=Zeng|first11=Rui|last12=Xu|first12=Gang|title=Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia|journal=Journal of the American Society of Nephrology|volume=31|issue=6|year=2020|pages=1157–1165|issn=1046-6673|doi=10.1681/ASN.2020030276}}</ref> But, these findings are not significantly different with other critical diseases.
| |
|
| |
|
| =[[Xyz risk factors|Risk Factors]]= | | |- |
| *Severe [[COVID-19]] pneumonia and [[severe acute respiratory distress syndrome]] are associated with developing [[AKI]].<ref name="PeiZhang2020">{{cite journal|last1=Pei|first1=Guangchang|last2=Zhang|first2=Zhiguo|last3=Peng|first3=Jing|last4=Liu|first4=Liu|last5=Zhang|first5=Chunxiu|last6=Yu|first6=Chong|last7=Ma|first7=Zufu|last8=Huang|first8=Yi|last9=Liu|first9=Wei|last10=Yao|first10=Ying|last11=Zeng|first11=Rui|last12=Xu|first12=Gang|title=Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia|journal=Journal of the American Society of Nephrology|volume=31|issue=6|year=2020|pages=1157–1165|issn=1046-6673|doi=10.1681/ASN.2020030276}}</ref> | | |style="background: #DCDCDC; |''' [[Reticuldar]] pattern ''' |
| | | |
| | *Linear opacities in the lungs |
| | *Due to Interstitial thickening of inter and intralobular septa |
|
| |
|
| =[[Xyz screening|Screening]]=
| | |[[file |
|
| |
|
| =[[Xyz natural history, complications and prognosis|Natural History, Complications and Prognosis]]= | | |- |
| *Approximately half of the new AKI following COVID-19 is mild with good short-term prognosis. | | |style="background: #DCDCDC; |'''[[Air bronchogram]] ''' |
| *If no improvement occurs during follow-up, is contributed to higher mortality.<ref name="PeiZhang2020">{{cite journal|last1=Pei|first1=Guangchang|last2=Zhang|first2=Zhiguo|last3=Peng|first3=Jing|last4=Liu|first4=Liu|last5=Zhang|first5=Chunxiu|last6=Yu|first6=Chong|last7=Ma|first7=Zufu|last8=Huang|first8=Yi|last9=Liu|first9=Wei|last10=Yao|first10=Ying|last11=Zeng|first11=Rui|last12=Xu|first12=Gang|title=Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia|journal=Journal of the American Society of Nephrology|volume=31|issue=6|year=2020|pages=1157–1165|issn=1046-6673|doi=10.1681/ASN.2020030276}}</ref> | | | |
| =Diagnosis=
| | * Air-filled bronchi |
| [[Xyz diagnostic study of choice|Diagnostic study of choice]] | [[Xyz history and symptoms|History and Symptoms]] | [[Xyz physical examination|Physical Examination]] | [[Xyz laboratory findings|Laboratory Findings]] | [[Xyz electrocardiogram|Electrocardiogram]] | [[Xyz x ray|X-Ray Findings]] | [[Xyz echocardiography and ultrasound|Echocardiography and Ultrasound]] | [[Xyz CT scan|CT-Scan Findings]] | [[Xyz MRI|MRI Findings]] | [[Xyz other imaging findings|Other Imaging Findings]] | [[Xyz other diagnostic studies|Other Diagnostic Studies]]
| | *Low attenuated areas in the lung |
| | |[[file |
|
| |
|
| =Treatment=
| | |- |
| [[Xyz medical therapy|Medical Therapy]] | [[Xyz interventions|Interventions]] | [[Xyz surgery|Surgery]] | [[Xyz primary prevention|Primary Prevention]] | [[Xyz secondary prevention|Secondary Prevention]] | [[Xyz cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Xyz future or investigational therapies|Future or Investigational Therapies]]
| | |style="background: #DCDCDC; |''' [[Bronchiectasis]] ''' |
| | | |
| | *irreversible dilatation of the lung airways |
| | * Bronchus diameter more than 1.5 cm |
| | *due to inflammation, obstruction and impaired clearance |
| | |[[file |
| | |} |
